People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins ...